Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic
Short half-life is one of the main causes of drug attrition in clinical development, which also leads to the failure of many leading compounds and hits to become drug candidates. Nowadays, nanomaterials have been applied to drug development to address this problem. In fact, the clinical application...
Gespeichert in:
| Veröffentlicht in: | Biomaterials science 2021-05, Vol.9 (1), p.3621-3637 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3637 |
|---|---|
| container_issue | 1 |
| container_start_page | 3621 |
| container_title | Biomaterials science |
| container_volume | 9 |
| creator | Wang, Ruyi Zhang, Zhongtao Liu, Bowen Xue, Jingwei Liu, Fulei Tang, Tongzhong Liu, Wenyuan Feng, Feng Qu, Wei |
| description | Short half-life is one of the main causes of drug attrition in clinical development, which also leads to the failure of many leading compounds and hits to become drug candidates. Nowadays, nanomaterials have been applied to drug development to address this problem. In fact, the clinical application of nanoparticles (NPs) is severely limited due to their rapid elimination by the reticuloendothelial system (RES)
in vivo
. In this paper, we aim to summarize representative strategies on prolonging the circulation time for bridging the gap between excellent pharmaceutics and proper half-life and encourage clinical translation.
The strategies for designing long-circulating nanoparticles. |
| doi_str_mv | 10.1039/d0bm02221g |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2528924798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528465434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-aded1378bef5b7cf37ac0334e0661af569fb33e91facbe122561a8442152cdd33</originalsourceid><addsrcrecordid>eNpd0c9LwzAUB_Agisr04l0JeBGxml9tWm86dQoTD-q5pGnSZaTNTFLE_9666URzyePlw-ORLwAHGJ1jRIuLGlUtIoTgZgPsEsR4wnJWbK5rinbAfghzNBzOC5ThbbBDGUJ5mvNdYJ-jF1E1RgWonYdxpmCtgmk66DTsROcWwkcjrQqXMMSvumvgu4kzaF3XJNJ42Vux7P7RZ1B710IrKhgdlNZ0Ru6BLS1sUPvf9wi83t2-jO-T6dPkYXw1TSSlPCaiVjWmPK-UTisuNeVCIkqZQlmGhU6zQleUqgJrISuFCUmHds4YwSmRdU3pCJys5i68e-tViGVrglTWik65PpQkJXlBGC_ygR7_o3PX-27YbqlYljLKBnW6UtK7ELzS5cKbVviPEqPyK4byBl0_LmOYDPjoe2Rftape059PH8DhCvgg16-_OdJP_umM3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528465434</pqid></control><display><type>article</type><title>Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><creator>Wang, Ruyi ; Zhang, Zhongtao ; Liu, Bowen ; Xue, Jingwei ; Liu, Fulei ; Tang, Tongzhong ; Liu, Wenyuan ; Feng, Feng ; Qu, Wei</creator><creatorcontrib>Wang, Ruyi ; Zhang, Zhongtao ; Liu, Bowen ; Xue, Jingwei ; Liu, Fulei ; Tang, Tongzhong ; Liu, Wenyuan ; Feng, Feng ; Qu, Wei</creatorcontrib><description>Short half-life is one of the main causes of drug attrition in clinical development, which also leads to the failure of many leading compounds and hits to become drug candidates. Nowadays, nanomaterials have been applied to drug development to address this problem. In fact, the clinical application of nanoparticles (NPs) is severely limited due to their rapid elimination by the reticuloendothelial system (RES)
in vivo
. In this paper, we aim to summarize representative strategies on prolonging the circulation time for bridging the gap between excellent pharmaceutics and proper half-life and encourage clinical translation.
The strategies for designing long-circulating nanoparticles.</description><identifier>ISSN: 2047-4830</identifier><identifier>EISSN: 2047-4849</identifier><identifier>DOI: 10.1039/d0bm02221g</identifier><identifier>PMID: 34008587</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Half-Life ; Nanomaterials ; Nanoparticles</subject><ispartof>Biomaterials science, 2021-05, Vol.9 (1), p.3621-3637</ispartof><rights>Copyright Royal Society of Chemistry 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-aded1378bef5b7cf37ac0334e0661af569fb33e91facbe122561a8442152cdd33</citedby><cites>FETCH-LOGICAL-c337t-aded1378bef5b7cf37ac0334e0661af569fb33e91facbe122561a8442152cdd33</cites><orcidid>0000-0003-0909-0316 ; 0000-0003-2075-9033</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34008587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ruyi</creatorcontrib><creatorcontrib>Zhang, Zhongtao</creatorcontrib><creatorcontrib>Liu, Bowen</creatorcontrib><creatorcontrib>Xue, Jingwei</creatorcontrib><creatorcontrib>Liu, Fulei</creatorcontrib><creatorcontrib>Tang, Tongzhong</creatorcontrib><creatorcontrib>Liu, Wenyuan</creatorcontrib><creatorcontrib>Feng, Feng</creatorcontrib><creatorcontrib>Qu, Wei</creatorcontrib><title>Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic</title><title>Biomaterials science</title><addtitle>Biomater Sci</addtitle><description>Short half-life is one of the main causes of drug attrition in clinical development, which also leads to the failure of many leading compounds and hits to become drug candidates. Nowadays, nanomaterials have been applied to drug development to address this problem. In fact, the clinical application of nanoparticles (NPs) is severely limited due to their rapid elimination by the reticuloendothelial system (RES)
in vivo
. In this paper, we aim to summarize representative strategies on prolonging the circulation time for bridging the gap between excellent pharmaceutics and proper half-life and encourage clinical translation.
The strategies for designing long-circulating nanoparticles.</description><subject>Half-Life</subject><subject>Nanomaterials</subject><subject>Nanoparticles</subject><issn>2047-4830</issn><issn>2047-4849</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0c9LwzAUB_Agisr04l0JeBGxml9tWm86dQoTD-q5pGnSZaTNTFLE_9666URzyePlw-ORLwAHGJ1jRIuLGlUtIoTgZgPsEsR4wnJWbK5rinbAfghzNBzOC5ThbbBDGUJ5mvNdYJ-jF1E1RgWonYdxpmCtgmk66DTsROcWwkcjrQqXMMSvumvgu4kzaF3XJNJ42Vux7P7RZ1B710IrKhgdlNZ0Ru6BLS1sUPvf9wi83t2-jO-T6dPkYXw1TSSlPCaiVjWmPK-UTisuNeVCIkqZQlmGhU6zQleUqgJrISuFCUmHds4YwSmRdU3pCJys5i68e-tViGVrglTWik65PpQkJXlBGC_ygR7_o3PX-27YbqlYljLKBnW6UtK7ELzS5cKbVviPEqPyK4byBl0_LmOYDPjoe2Rftape059PH8DhCvgg16-_OdJP_umM3g</recordid><startdate>20210518</startdate><enddate>20210518</enddate><creator>Wang, Ruyi</creator><creator>Zhang, Zhongtao</creator><creator>Liu, Bowen</creator><creator>Xue, Jingwei</creator><creator>Liu, Fulei</creator><creator>Tang, Tongzhong</creator><creator>Liu, Wenyuan</creator><creator>Feng, Feng</creator><creator>Qu, Wei</creator><general>Royal Society of Chemistry</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0909-0316</orcidid><orcidid>https://orcid.org/0000-0003-2075-9033</orcidid></search><sort><creationdate>20210518</creationdate><title>Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic</title><author>Wang, Ruyi ; Zhang, Zhongtao ; Liu, Bowen ; Xue, Jingwei ; Liu, Fulei ; Tang, Tongzhong ; Liu, Wenyuan ; Feng, Feng ; Qu, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-aded1378bef5b7cf37ac0334e0661af569fb33e91facbe122561a8442152cdd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Half-Life</topic><topic>Nanomaterials</topic><topic>Nanoparticles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ruyi</creatorcontrib><creatorcontrib>Zhang, Zhongtao</creatorcontrib><creatorcontrib>Liu, Bowen</creatorcontrib><creatorcontrib>Xue, Jingwei</creatorcontrib><creatorcontrib>Liu, Fulei</creatorcontrib><creatorcontrib>Tang, Tongzhong</creatorcontrib><creatorcontrib>Liu, Wenyuan</creatorcontrib><creatorcontrib>Feng, Feng</creatorcontrib><creatorcontrib>Qu, Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><jtitle>Biomaterials science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ruyi</au><au>Zhang, Zhongtao</au><au>Liu, Bowen</au><au>Xue, Jingwei</au><au>Liu, Fulei</au><au>Tang, Tongzhong</au><au>Liu, Wenyuan</au><au>Feng, Feng</au><au>Qu, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic</atitle><jtitle>Biomaterials science</jtitle><addtitle>Biomater Sci</addtitle><date>2021-05-18</date><risdate>2021</risdate><volume>9</volume><issue>1</issue><spage>3621</spage><epage>3637</epage><pages>3621-3637</pages><issn>2047-4830</issn><eissn>2047-4849</eissn><abstract>Short half-life is one of the main causes of drug attrition in clinical development, which also leads to the failure of many leading compounds and hits to become drug candidates. Nowadays, nanomaterials have been applied to drug development to address this problem. In fact, the clinical application of nanoparticles (NPs) is severely limited due to their rapid elimination by the reticuloendothelial system (RES)
in vivo
. In this paper, we aim to summarize representative strategies on prolonging the circulation time for bridging the gap between excellent pharmaceutics and proper half-life and encourage clinical translation.
The strategies for designing long-circulating nanoparticles.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>34008587</pmid><doi>10.1039/d0bm02221g</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0909-0316</orcidid><orcidid>https://orcid.org/0000-0003-2075-9033</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-4830 |
| ispartof | Biomaterials science, 2021-05, Vol.9 (1), p.3621-3637 |
| issn | 2047-4830 2047-4849 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2528924798 |
| source | MEDLINE; Royal Society Of Chemistry Journals 2008- |
| subjects | Half-Life Nanomaterials Nanoparticles |
| title | Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T08%3A06%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20the%20design%20of%20nanoparticles:%20starting%20with%20long-circulating%20nanoparticles,%20from%20lab%20to%20clinic&rft.jtitle=Biomaterials%20science&rft.au=Wang,%20Ruyi&rft.date=2021-05-18&rft.volume=9&rft.issue=1&rft.spage=3621&rft.epage=3637&rft.pages=3621-3637&rft.issn=2047-4830&rft.eissn=2047-4849&rft_id=info:doi/10.1039/d0bm02221g&rft_dat=%3Cproquest_cross%3E2528465434%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528465434&rft_id=info:pmid/34008587&rfr_iscdi=true |